Australia's TGA reiterates: Nicotine pouches are prescription drugs in Australia, and unapproved products pose safety risks.

Aug.08.2025
Australia's TGA reiterates: Nicotine pouches are prescription drugs in Australia, and unapproved products pose safety risks.
Illegal sale of nicotine pouches in Australia is on the rise, posing health risks and legal consequences.

Key points:

 

·Illegal sales on the rise: The illegal advertising and online sales of nicotine pouches in Australia have increased, with many products coming from overseas and not approved by the Therapeutic Goods Administration (TGA). 

·Legal restrictions: Nicotine pouches are considered prescription drugs in Australia and cannot be sold in retail stores or advertised. 

·Health risks: Nicotine pouches contain high concentrations of nicotine, which can lead to addiction, brain development issues, and various side effects. 

·Legal consequences: Those who violate the law may face up to 5 years in prison and a fine of up to 1.32 million Australian dollars (approximately 860,000 US dollars). 

·Consumer advice: Before purchasing nicotine pouches, make sure to have a prescription or written authorization, and consult a doctor or pharmacist.

 


 

According to the official website of the Therapeutic Goods Administration (TGA) on August 7th, illegal advertisements and online sales of nicotine pouches in Australia have increased, with many of these products being imported from overseas. It is important to note that nicotine pouches are considered prescription drugs in Australia and currently no nicotine pouch products have been approved by the TGA. This means that nicotine pouch products have not undergone safety, quality, and efficacy testing in Australia.

 

Nicotine pouches are small pouches placed between the lips and gums, typically containing varying strengths of nicotine, as well as other ingredients such as sweeteners and flavors. They are often marketed as a "smoke-free" or "tobacco-free" alternative to e-cigarettes. However, there is little evidence to suggest that they are effective in helping people quit smoking or reduce their dependence on nicotine.

 

According to Australian law, nicotine pouches are classified as prescription medications. This means that they:

 

It cannot be sold in retail stores or tobacco shops; advertising is not allowed; it cannot be imported or sold without approval from the TGA or a valid written authorization or prescription from an Australian healthcare practitioner.

 

Some states may have additional restrictions. For example, in South Australia, nicotine pouches are banned under new tobacco and e-cigarette legislation.

 

Violating the law could lead to serious consequences. According to the 1989 Therapeutic Goods Act, significant fines, including up to 5 years imprisonment, a maximum fine of 1.32 million Australian dollars (approximately 860,000 US dollars), or both, may be imposed for illegal advertising and supply activities. Additionally, further fines may be imposed under state and territory medicines and poisons laws.

 

Nicotine pouches can be dangerous. Some nicotine pouches contain high concentrations of nicotine, which may lead to side effects. They are not produced according to Australian standards, and their safety has not been inspected.

 

Nicotine is highly addictive, especially for young people. It may interfere with brain development, affecting memory, learning, and attention.

 

Side effects associated with nicotine pouches include: increased heart rate and high blood pressure; nausea, dizziness, and headaches; mouth ulcers.

 

Some products may not list nicotine on the ingredients label. The lack of clear ingredient information on the label could potentially lead to delayed treatment if the product is ingested, which is especially dangerous for children. Furthermore, mislabeled products are considered counterfeit and should not be imported or supplied under any circumstances.

 

Before purchasing nicotine pouches, make sure you have a prescription or written authorization, and meet all legal requirements. Discuss with your doctor or pharmacist how to properly obtain unapproved medications. Read information from the Therapeutic Goods Administration (TGA) regarding unapproved therapeutic goods.

 

The Therapeutic Goods Administration (TGA) has approved nicotine replacement therapies, including patches, sprays, and lozenges. Unlike nicotine pouches, these products meet Australian quality, safety, and effectiveness standards. They are available for purchase at pharmacies and supermarkets.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Sweden Becomes First EU Country to Reach Smoke-Free Status as Daily Smoking Falls to 4.8%
Sweden Becomes First EU Country to Reach Smoke-Free Status as Daily Smoking Falls to 4.8%
According to the latest CAN report and multiple media reports, Sweden’s daily smoking rate fell to 4.8% in 2025, below the commonly used 5% smoke-free threshold, making it the first EU country to reach that benchmark.
News
Jun.05
Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
China’s tobacco tax debate is moving from whether to raise prices to how the tax system should be designed. At a Beijing forum on World No Tobacco Day, experts discussed higher specific excise taxes, minimum tax burdens and dynamic adjustments linked to income and inflation. The issue also connects to China’s broader consumption tax reform, health financing and chronic disease costs. Public reports did not mention e-cigarettes, heated tobacco, nicotine pouches or other new nicotine products.
Jun.11
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japanese Tobacco (JT) reports Q1 2026 revenue of 924 billion yen, a 15.2% increase; operating profit rises 24.7%.
May.08 by 2FIRSTS.ai
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary resigned on May 12 after opposing the Trump administration’s push to authorize fruit-flavored vaping products, according to reporting by The New York Times. Makary reportedly objected over concerns that flavored vapes could attract young people and refused to support broader approvals.
News
May.13
PMI Highlights 43 Million Smoke-Free Users at Stockholm Summit
PMI Highlights 43 Million Smoke-Free Users at Stockholm Summit
Philip Morris International says about 43 million adults worldwide now use its smoke-free products, with nearly 70% having stopped using cigarettes and smoke-free products accounting for about 43% of its net revenues.
Jun.18
China Tobacco International HK Warns First-Half Revenue May Fall 25%-30%, Tobacco Leaf and Duty-Free Exposure Highlight Reliance on Traditional Tobacco
China Tobacco International HK Warns First-Half Revenue May Fall 25%-30%, Tobacco Leaf and Duty-Free Exposure Highlight Reliance on Traditional Tobacco
CTIHK expects first-half 2026 revenue to fall 25%-30%, mainly due to lower tobacco leaf imports and delayed cigarette shipments to China’s domestic duty-free market. Its 2025 revenue mix—nearly 90% from tobacco leaf-related businesses and less than 1% from new tobacco products—shows continued exposure to traditional supply chains and trade variables.
Jun.18